The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care
复制标题
DOI：
10.1002/cpt.1567
复制
发表时间：
2019-08-21
影响因子：
6.7
通讯作者：
O'Donnell, Peter H.
中科院分区：
文献类型：
--
作者：
Truong, Tien M.;Apfelbaum, Jeffrey;O'Donnell, Peter H.
围手术期常用的许多药物具有众所周知的药物基因组学相关性，个体间反应差异可导致疗效降低和/或药物不良事件（ADE），导致严重的患者发病率和死亡率。我们描述了我们的机构项目，“ImPreSS试验”，它测试了一个模型，是否先发制人的药物基因组学基因分型和临床实施的结果到围手术期的工作流程将有助于围手术期用药决策，并最终提高高风险的药物反应，这一关键的医疗保健设置。
Many medications commonly used in the perioperative setting have well-known pharmacogenomic associations and interindividual variability in responses can lead to decreased efficacy and/or adverse drug events (ADEs), resulting in devastating patient morbidity and mortality. We describe our institutional project,“The ImPreSS Trial”, which tests a model of whether preemptive pharmacogenomic genotyping and clinical implementation of results into the perioperative workflow will aid perioperative medication decision-making, and ultimately improve the high-stakes drug responses of this critical healthcare setting.